Companion diagnostic Introduction (What it is)
A Companion diagnostic is a medical test used to help guide the use of a specific cancer treatment.
It looks for a biomarker (a measurable feature such as a gene change or protein level) that predicts whether a therapy is more or less likely to help.
It is most commonly used in precision oncology, where treatments are matched to tumor biology.
It may be performed on tumor tissue, blood, or sometimes other samples, depending on the cancer and test.
Why Companion diagnostic used (Purpose / benefits)
Modern cancer care increasingly relies on selecting therapies based on how a tumor behaves at a molecular level, not only where it started (such as lung, breast, or colon). Many systemic cancer treatments—especially targeted therapies and some immunotherapies—work well only when a specific biomarker is present (or absent). This is the core problem a Companion diagnostic helps solve: identifying the right patients for a specific treatment and avoiding treatment that is unlikely to help.
In practical terms, a Companion diagnostic supports:
- Treatment selection: It can help clinicians determine whether a particular drug is appropriate for a person’s tumor biology.
- Safety and risk reduction: Some tests are used to identify patients who may be at higher risk of serious toxicity from a specific therapy, or who should avoid it.
- Efficiency in care: By narrowing choices, it can reduce “trial-and-error” prescribing and shorten the time to a more tailored plan.
- Clinical confidence and communication: A documented biomarker result can make the rationale for a treatment plan clearer for patients and care teams.
- Consistency across settings: Standardized assays and reporting can support more uniform decision-making across institutions, though practices still vary by region and cancer type.
A Companion diagnostic does not replace core cancer steps such as diagnosis and staging. Instead, it adds a biomarker layer to guide therapy within an established oncology pathway.
Indications (When oncology clinicians use it)
Oncology clinicians may consider a Companion diagnostic in scenarios such as:
- A new diagnosis of a cancer type where biomarker-driven treatments are part of standard care (varies by cancer type and stage)
- Metastatic or recurrent disease when systemic therapy options are being chosen
- Considering a targeted therapy that requires a specific gene alteration or protein expression level
- Considering an immunotherapy where a biomarker may help estimate likelihood of benefit (the role varies by tumor type)
- When prior treatment has stopped working and the team is evaluating next-line options
- When a clinical trial requires a biomarker result for eligibility
- When there is limited time to make a treatment decision and a validated rapid test is available (availability varies)
- When a cancer’s histology (microscopic appearance) suggests certain biomarkers may be more likely and worth testing
Contraindications / when it’s NOT ideal
A Companion diagnostic is not “unsafe” in the way a surgery might be, but there are situations where it may be less suitable, less informative, or not feasible:
- Insufficient or poor-quality sample: Too little tumor tissue, degraded tissue, or a specimen with too few tumor cells can lead to an uninterpretable result.
- Timing and urgency constraints: If a patient needs immediate treatment and testing would cause a delay, clinicians may use alternative planning approaches while testing is pending (varies by case).
- Low likelihood of actionability: If no treatment option would change based on the biomarker (for example, due to cancer stage, prior therapies, or access limitations), broad testing may be lower yield.
- High chance of false-negative due to tumor biology: Some tumors are heterogeneous (different areas differ), so a single biopsy may miss a biomarker present elsewhere.
- Confounding factors for certain assays: Recent transfusion, low tumor DNA fraction in blood, or technical issues can affect some blood-based tests (details vary by assay).
- When a different test is more appropriate: For some questions, a standard pathology review, imaging, or a different biomarker method may better answer the clinical need.
- When results would not be clinically valid: If the test is not validated for that tumor type or specimen type, clinicians may prefer a different validated approach.
How it works (Mechanism / physiology)
A Companion diagnostic works by detecting a biomarker linked to the use of a specific therapy. In oncology, biomarkers often reflect underlying tumor biology such as:
- DNA changes (mutations, insertions/deletions, gene fusions, copy number changes) that can drive cancer growth
- RNA patterns that indicate gene fusions or expression changes
- Protein expression on tumor cells or immune cells that may correlate with response to a drug
- Cell signaling pathways that a targeted therapy is designed to block or modulate
Clinical pathway (high level)
- A therapy has a defined biomarker requirement or recommendation.
- A test detects that biomarker in tumor tissue or blood using a standardized method.
- Results are interpreted in context (cancer type, stage, prior treatments, performance status, comorbidities, and patient goals).
- Treatment is selected or avoided based on whether the biomarker meets criteria for that therapy.
Tissue and organ context
Most Companion diagnostic testing is performed on:
- Tumor tissue from a biopsy or surgery specimen (solid tumors)
- Blood for circulating tumor DNA (often called a “liquid biopsy”) in some settings
- Bone marrow or blood cells for hematologic malignancies, depending on the disease
Onset, duration, reversibility (what applies here)
A Companion diagnostic itself does not have an “onset” or “duration” like a medication. Instead, the key concepts are:
- Turnaround time: How quickly results return can affect treatment sequencing (varies by lab and test type).
- Stability of the biomarker: Some biomarkers are relatively stable over time, while others can change after treatment or as the tumor evolves.
- Re-testing considerations: Repeat testing may be considered if disease progresses, a new biopsy is obtained, or a different therapy is being considered (varies by clinician and case).
Companion diagnostic Procedure overview (How it’s applied)
A Companion diagnostic is typically used as part of an oncology workflow rather than as a stand-alone procedure. A simplified overview looks like this:
- Evaluation/exam: Symptoms, history, exam, and review of prior records.
- Imaging/biopsy/labs: Imaging helps locate disease; a biopsy or surgical specimen confirms cancer type and provides material for testing; baseline bloodwork may be obtained.
- Pathology confirmation: A pathologist evaluates the tissue to confirm diagnosis and key features (tumor type, grade, and other foundational markers).
- Staging: Imaging and pathology findings are combined to assign stage (extent of disease), which helps frame treatment intent and options.
- Biomarker test selection: The oncology team determines whether a Companion diagnostic is indicated based on cancer type, stage, and potential therapies.
- Sample preparation and testing: The lab performs the assay (for example, immunohistochemistry, PCR, or next-generation sequencing) under validated conditions.
- Reporting and interpretation: Results are reported with technical details and clinical interpretive notes; clinicians interpret results alongside the patient’s overall situation.
- Treatment planning: The care team selects therapy (systemic therapy, radiation, surgery, or combinations) and supportive care based on goals and evidence.
- Response assessment: Imaging, labs, and symptom tracking are used to assess benefit and tolerability; some biomarkers may be monitored over time in selected cases.
- Follow-up/survivorship: Ongoing monitoring, late-effect screening, rehabilitation, and survivorship planning as appropriate (varies by cancer type and stage).
Types / variations
Companion diagnostics can differ by what they measure, how they are measured, and where they fit in care.
By testing method
- Immunohistochemistry (IHC): Uses antibodies to detect protein expression in tumor tissue. Often reported as a score or percentage, depending on the biomarker.
- In situ hybridization (ISH/FISH): Detects gene amplifications or rearrangements in cells using labeled probes.
- PCR-based assays: Detect specific, known DNA changes with high sensitivity for targeted alterations.
- Next-generation sequencing (NGS): Tests many genes at once for multiple alteration types; may be tumor-only or paired with normal DNA depending on the approach.
- Liquid biopsy (blood-based testing): Detects circulating tumor DNA; may be used when tissue is limited or when tracking tumor evolution is important (performance varies by context).
- Flow cytometry and related methods (more common in hematologic cancers): Characterizes cell surface markers and cell populations to support therapy decisions in certain diseases.
By clinical use case
- Therapy selection tests: Identify patients more likely to benefit from a specific drug based on a required biomarker.
- Therapy avoidance/safety tests: Identify patients at higher risk of toxicity or low likelihood of benefit for a specific therapy.
- Single-biomarker vs multi-biomarker panels: Some tests focus on one marker tied to one drug, while others evaluate several markers that may inform multiple options.
- Solid-tumor vs hematologic applications: Solid tumors often rely on tissue-based profiling; blood and marrow cancers may use blood or marrow specimens and immune-phenotyping.
By care setting
- Outpatient testing: Many samples are collected and processed without hospital admission.
- Inpatient/urgent contexts: Testing may occur during hospitalization, especially when a rapid treatment decision is needed; feasibility varies.
Pros and cons
Pros:
- Helps match a therapy to tumor biology, supporting more personalized care
- May reduce exposure to treatments unlikely to help
- Can clarify eligibility for certain targeted therapies or immunotherapies
- May inform clinical trial options when standard therapies are limited
- Encourages standardized biomarker reporting and multidisciplinary discussion
- Can be performed on existing pathology specimens in some cases, reducing additional procedures
Cons:
- Requires adequate tissue or a suitable blood sample; results can be indeterminate
- Not all cancers have validated biomarker-linked therapies; usefulness varies by cancer type and stage
- Biomarkers can change over time; a past result may not reflect current tumor biology
- Results may be complex and require careful interpretation to avoid over- or under-estimating relevance
- Turnaround time can delay final treatment selection in some workflows
- Insurance coverage and access vary, and out-of-pocket costs can be unpredictable
- A positive biomarker does not guarantee a response, and a negative result does not always eliminate all options
Aftercare & longevity
A Companion diagnostic does not create “aftercare” in the same way a surgery or chemotherapy regimen does, but it does shape what follow-up looks like and how long a result remains useful.
Key factors that influence the ongoing value (“longevity”) of a Companion diagnostic result include:
- Cancer type and stage: Early-stage care may focus on local treatment, while advanced-stage care often relies more on systemic therapy selection.
- Tumor biology and heterogeneity: Tumors can contain mixed subclones; a biomarker may be present in one area and absent in another.
- Treatment pressure and evolution: As treatments are applied, resistant clones can emerge, and biomarker profiles may change.
- Specimen timing and source: Results from a recent metastatic biopsy may better reflect current disease than older primary-tumor samples (varies by cancer).
- Quality of follow-up and response assessment: Imaging schedules, lab monitoring, and symptom review help determine whether a biomarker-guided therapy is helping.
- Supportive care and comorbidities: Tolerability can influence whether a selected therapy can be continued as planned.
- Access to oncology services: Availability of retesting, subspecialty pathology review, and clinical trials can affect how biomarker information is used over time.
- Survivorship planning: For some cancers, biomarker information may be referenced later if disease recurs, though clinical relevance may change.
Alternatives / comparisons
A Companion diagnostic is one tool within a larger decision framework. Common alternatives or related approaches include:
- Standard pathology and staging without advanced biomarker testing: For some cancers, treatment decisions rely mainly on histology, grade, stage, and patient factors. Biomarker testing may be optional or reserved for specific stages.
- Observation or active surveillance: In selected low-risk situations (varies by cancer type), clinicians may monitor rather than start immediate treatment; biomarker testing may or may not play a role.
- Surgery vs radiation vs systemic therapy: Local therapies (surgery/radiation) are guided primarily by stage and anatomy, while systemic therapy is more likely to be biomarker-informed. Many patients receive combinations, depending on the clinical plan.
- Chemotherapy vs targeted therapy vs immunotherapy: Chemotherapy is typically chosen based on cancer type and stage; targeted therapy often requires a specific biomarker; immunotherapy may be guided by biomarkers in some cancers but not all.
- Empiric treatment vs biomarker-driven treatment: When biomarkers are unavailable or results are pending, clinicians may choose a broadly active regimen. The balance depends on urgency, evidence, and patient factors.
- Standard care vs clinical trials: Trials may offer access to biomarker-driven treatments and testing strategies not available in routine practice. Trial eligibility often depends on specific biomarker criteria and other clinical factors.
Companion diagnostic Common questions (FAQ)
Q: Is a Companion diagnostic the same as a genetic test?
A: Not exactly. Many Companion diagnostic tests look for genetic changes in the tumor, but they are designed specifically to guide use of a particular therapy. Some focus on proteins rather than DNA, and some use blood instead of tumor tissue.
Q: Will the test be painful or require anesthesia?
A: The test itself is performed in a lab, so there is no pain from the analysis. Any discomfort depends on how the sample is obtained—such as a needle biopsy or blood draw. Anesthesia or sedation may be used for certain biopsy procedures, depending on the site and approach.
Q: How long does it take to get results?
A: Turnaround time varies by test type, laboratory workflow, and whether the sample needs additional processing. Some single-marker tests may return faster than broad multi-gene panels. Your care team typically plans treatment discussions around expected timing.
Q: How accurate is a Companion diagnostic?
A: Accuracy depends on the specific assay, sample quality, and how the biomarker is defined for that cancer and therapy. False negatives can happen if there is not enough tumor in the sample or if the tumor is biologically heterogeneous. Results are interpreted alongside pathology, imaging, and the clinical situation.
Q: Can the results change over time?
A: Yes. Tumors can evolve, especially after exposure to treatment, and new resistant changes may appear. Clinicians may consider repeat testing if the cancer progresses or if a new therapy choice depends on updated biomarker information.
Q: Are there side effects from the test?
A: The lab analysis does not cause side effects. Potential side effects relate to sample collection, such as bruising from a blood draw or procedure-related risks from a biopsy. The specific risks depend on the biopsy site and technique.
Q: What does it mean if my biomarker is “positive,” “negative,” or “inconclusive”?
A: “Positive” generally means the biomarker meets criteria linked to a therapy option; “negative” means it does not. “Inconclusive” or “insufficient” often means the sample was not adequate or the assay could not produce a reliable result. Clinicians may consider retesting with a new sample or a different method if it would change management.
Q: Will a positive result guarantee the treatment will work?
A: No. A biomarker can indicate a higher likelihood of benefit or appropriateness for a drug, but responses vary by cancer type and stage, overall health, and other tumor factors. Treatment decisions usually also consider potential risks, alternative options, and patient goals.
Q: How much does Companion diagnostic testing cost, and is it covered by insurance?
A: Costs and coverage vary widely based on the test, the lab, the diagnosis, and the insurance plan. Some tests tied to specific therapies are more commonly covered, while broader panels may require prior authorization. Many centers have financial counselors or billing specialists who can help clarify expected charges.
Q: Does biomarker testing affect fertility or pregnancy?
A: The testing itself does not affect fertility because it is performed on a sample outside the body. However, treatments chosen based on the results may have fertility or pregnancy implications. Clinicians often discuss fertility preservation and pregnancy considerations before starting systemic therapy, depending on age, treatment plan, and patient priorities.